Tyra Biosciences(TYRA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights - SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - -IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC - - Announced Chief Medical Of icer transition plan; search for an external candidate underway with guidance from Science & Technology ...